Side-by-side research comparison of Exenatide and Liraglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 2 head-to-head studies plus 14 on Exenatide and 377 on Liraglutide.
| Exenatide | Liraglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 14 | 377 |
| Highest evidence tier | meta analysis | rct |
| Evidence tier mix | rct · 3 meta analysis · 1 other · 5 cohort · 1 review · 1 | rct · 8 cohort · 2 review · 2 in vitro · 2 preclinical animal · 1 |
| Studies with explicit sample size | 4 | 5 |
| Head-to-head studies in corpus | 2 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Exenatide and Liraglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Exenatide COA records so far — not enough for a meaningful purity aggregate yet.
We tested 9 Liraglutide batches across 4 manufacturers, 99.58% avg purity.
Studies in our corpus that mention both Exenatide and Liraglutide — the gold-standard direct comparison evidence.
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a novel mechanism to the already establishe…
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
Looking for vendor-level purity, endotoxin, and HPLC data on Exenatide or Liraglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.